Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Christian Kinch assumes role as senior advisor to Bactiguard and declines re-election to the board

The Nomination Committee of Bactiguard Holding AB (the "Company") today informs about the proposal regarding the composition of the Board of Directors for the Annual General Meeting on 14 May 2024.The Nomination Committee proposes reelection of Thomas von Koch, Dr Richard Kuntz, Professor Anna Martling, Magdalena Persson and Jan Ståhlberg as Board Members. Christian Kinch has declined re-election. As the Company has appointed a new permanent CEO with effect from the Annual General Meeting at the latest, the Nomination Committee further proposes that Thomas von Koch is re-elected as the

Invitation to the presentation of Midsona’s interim report January- March 2024

Midsona invites you to a presentation of the company’s interim report January-March 2024 on Thursday, April 25, 2024, at 11.00 am CEST. The report will be published the same day at 08.00 am CEST.CEO Peter Åsberg and CFO Max Bokander will present the results. After the presentation, there will be an opportunity to ask questions. The presentation will be held in English.   The webcast can be accessed via this link: https://ir.financialhearings.com/midsona-q1-report-2024 To attend the presentation via teleconference and to ask questions, please klick on the link. After your

Icore Solutions acquired by Volaris Group "Helping open doors to new business opportunities"

Icore Solutions announces its acquisition by Volaris Group. The acquisition helps position Icore for continued growth and development.  “By being part of a larger company and having the support of Volaris, we get access to resources and expertise that can help open doors to new business opportunities that were previously inaccessible to us”, says Mikael Boquist, CEO of Icore. Mikael Boquist, CEO Icore Solutions, and Christian Lanng, Portfolio Manager, Nordics and UK & Portfolio COO, Volaris Group. Photo by Fredrik Bankler. Volaris Group specializes in the acquisition and growth

Inwido´s Annual and Sustainability Report for 2023 is published

Inwido´s Annual and Sustainability Report for 2023 is now available on Inwidos website. A printed version of the Annual and Sustainability Report can be ordered on the website, in Swedish and English.Stable development demonstrates the strength of the business model As well as delivering stable profitability, Inwido strengthened its cash flow and ended the year with continued low indebtedness, despite the fact that the Company completed its largest acquisition to date during 2023. The year was characterized by inflation, high interest rates and war in both Europe and the Middle East.

BioStock: BiBB’s CEO - “Patient cases fortify our confidence in EndoDrill”

BiBBInstruments' cancer biopsy device, EndoDrill, has earned high praise from physicians who conducted the first clinical cases at Karolinska University Hospital in Stockholm, Sweden. This positive feedback follows the endorsement of EndoDrill as a "game-changer" in endoscopic ultrasound sampling by the Medical Director of Endoscopy at UC Davis in the US. BioStock spoke with BiBB’s CEO Fredrik Lindblad to learn more.Read the article at biostock.se: https://www.biostock.se/en/2024/04/bibbs-ceo-patient-cases-fortify-our-confidence-in-endodrill/This is a press release from BioStock -

Inhalation Sciences AB (publ) releases Annual Report 2023

Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/ CEO comments 2023 was another year in which we continued to take new market share and successfully deliver on our strategic goals. Over the past three years, revenue has increased steadily by 29% from 2021 to 2022 and now by 44% from 2022 to 2023. At the same time, we have also significantly improved our operating profit during the same period. With this positive development, we

NOTICE OF ANNUAL GENERAL MEETING IN BALCO GROUP AB (publ)

The shareholders in Balco Group AB, reg. no. 556821-2319, are invited to the Annual General Meeting, to be held on Tuesday May 14, 2024, at 3.00 pm at Kök 11, Honnörsgatan 15 in Växjö. Registration starts at 2.30 pm. The Board of Directors has, pursuant to Chapter 7, Section 4 a of the Swedish Companies Act (Sw. aktiebolagslagen), and Chapter 8 of the company's Articles of Association, decided that shareholders shall be able to exercise their voting rights by postal voting before the General Meeting. Consequently, shareholders may choose to exercise their voting rights at the Annual

CONVENING NOTICE OF ANNUAL GENERAL MEETING OF ORGANOCLICK AB (publ)

Shareholders of OrganoClick AB (publ) (556704-6908) are hereby convened to the Annual General Meeting on Wednesday, May 15, 2024, at 17.00, at OrganoClick's head office and production facility, Linjalvägen 9, 187 66 Täby.PARTICIPATION Shareholders who wish to attend the AGM shall - be registered in OrganoClick’s shareholder register, kept by Euroclear Sweden AB, on Monday May 6, 2024, - no later than Wednesday, May 8, 2024, have notified their attendance, and any advisers, to the meeting. NOTIFICATION OF ATTENDANCE Notification of attendance can be made by email to ir@

Valmet renews its sustainability reporting

Valmet Oyj’s press release on April 11, 2024 at 9:30 a.m. EESTValmet renews its sustainability reporting practices. Since 2013 the company has published an annual sustainability report in line with the international GRI framework and reported to several leading sustainability ratings. In the current renewal, Valmet will focus on comprehensive reporting according to the EU's Corporate Sustainability Reporting Directive (CSRD), invest in the development of sustainability data and information systems required by this extensive reporting framework, and streamline participation in different

Notice of Annual General Meeting for Prevas AB

Unofficial English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence. The shareholders of Prevas AB, corporate registration number 556252-1384, are hereby given notice of the Annual General Meeting to be held on Wednesday May 15, 2024, at 6 p.m. in the company’s premises at Glödgargränd 14, Västerås, Sweden. RIGHT TO PARTICIPATE Shareholders wishing to attend the Annual General Meeting must: · partly be registered as shareholders in the share register held by

Checkin.com Group publishes Annual Report 2023

Checkin.com Group (STO:CHECK) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://group.checkin.com/investors/reports/For further information, please contact: Jonas Köpniwsky, Head of Communications Checkin.com Group, press@checkin.com Certified Adviser Checkin.com Group’s Certified Adviser is Carnegie Investment Bank AB (publ). About Checkin.com Group Checkin.com Group creates shareholder value through capital efficient growth achieved by strong organic growth

Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Canadian authorities issued a patent for the drug candidate CS1:s second patent family on Tuesday April 9. This strengthens and expands the immaterial rights (IPR) for Cereno’s drug candidate CS1, which is currently in clinical Phase II development as a treatment of the rare disease Pulmonary Arterial Hypertension (PAH).“I am pleased to announce that we have secured further immaterial rights for the drug candidate CS1 in

Initial data presented from the Investigator Initiated Trial (IIT) at Radboud University Medical Center using the CLS TRANBERG[®] system

Lund, Sweden April 11, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announces that for the first-time clinical data has been presented from the investigator-initiated study at Radboud University Medical Center in Nijmegen, the Netherlands, on the use of CLS’s MR-guided TRANBERG® system for Focal Laser Ablation (FLA) of localized prostate cancer.During the ECR (European Congress of Radiology) annual meeting in Vienna, Austria, an abstract by the principal investigator for the ongoing study at Radboud University Medical Center (RUMC), Prof. Jurgen Fütterer and

Fiskars Corporation to publish its Interim Report for January-March 2024 on April 25, 2024

Fiskars CorporationPress ReleaseApril 11, 2024 at 9.30 a.m. EEST Fiskars Corporation to publish its Interim Report for January-March 2024 on April 25, 2024 Fiskars Corporation will publish its Interim Report for January-March 2024 on April 25, 2024 at approximately 8:30 a.m. (EEST). The Interim Report will be available on the company's website www.fiskarsgroup.com after publication. Webcast A webcast on the first quarter results will be held on April 25, 2024 at 1:00 p.m. (EEST). It will be held in English and can be followed at https://fiskars.videosync.fi/q1-2024

Remedy Entertainment Plc: Share subscriptions based on stock options 2018 and 2019

Remedy Entertainment Plc       Stock exchange release          April 11, 2024, 9.30 a.m. EEST   Share subscriptions based on stock options 2018 and 2019 Between January 1 and March 31, 2024, a total of 36,250 Remedy Entertainment Plc’s new shares has been subscribed for with the company’s stock options 2018 and 2019. For subscriptions made with the stock options 2018 and 2019, the entire subscription price of EUR 261,105.00 will be entered in the reserve for invested unrestricted equity. After the trade registration the total amount of shares is 13,552,651. The shares

Invitation to Rottneros’ interim report for Q1 2024

The interim report for the first quarter 2024 will be published on 25 April 2024, at 8.00 CET, and is followed by a webcast live at 12.00 CET the same day.All participants can follow the presentation via the web link: Rottneros - Q1 Presentation 2024 - Finwire  Questions can be asked via the link in advance or during the presentation. You can also watch the presentation afterwards via Rottneros'  Youtube channel  and website: Reports and presentations | Rottneros 

Steady Energy and TVO Nuclear Services sign an agreement regarding nuclear power expertise services from Olkiluoto

TVO Nuclear Services (TVONS) and Steady Energy have signed a collaboration agreement related to the development of a nuclear heating plant, initially focusing on the planning of the nuclear facility’s operation and safety.The agreement gives Steady Energy access to Teollisuuden Voima Oyj’s (TVO) strong expertise in the planning and implementation of nuclear power plant projects as well as the operation, maintenance and service life management of the plants. Steady Energy aims to construct several 50-megawatt small modular reactors (SMRs) in Finland for the purpose of district heat

AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults

PRESS RELEASE - For UK consumer, medical and trade media only · The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) as an option in suitable patients for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventative treatments have not worked.[1] Suitable patients will soon have the option to be prescribed atogepant on the NHS in England and Wales. · The NICE

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 3.9883 USD IE00BLRPQH01 10 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3248 USD IE00BJXRZJ40 10 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

AstraZeneca increases 2024 dividend by 7%

11 April 2024  AstraZeneca increases 2024 dividend by 7% AstraZeneca announced today that the Board intends to increase the annualised dividend for 2024 by $0.20 to $3.10 per share, underlining the company's confidence in its performance and cash generation. This takes into account other capital allocation priorities as well as previously announced acquisitions and business development. Michel Demaré, Chair, AstraZeneca said: "The Board is delighted to announce a 7% increase to the dividend, taking it to $3.10 per share. This uplift is in line with our progressive dividend policy,

Invitation to Electrolux Group Q1 presentation

Electrolux Group results for the first quarter of 2024 will be published on April 26, 2024, at approx. 08.00 CET.A telephone conference will be held following the release of the results, starting at 09.00 CET. Jonas Samuelson, President and CEO, and Therese Friberg, CFO, will comment on the report. Information on how to join the telephone conference is available HERE . Slides used in the presentation and report will be available at the Group’s website, www.electroluxgroup.com/ir.

Invitation to the presentation of John Mattson’s interim report Q1 2024 on 25 April at 11:00 am (CEST)

Invitation by John Mattson to the webcast and the teleconference on 25 April at 11:00 a.m. (CEST) being held in conjunction with the publication of the company’s interim report for January-March 2024 at 8:00 a.m. (CEST) the same date.Investors, asset managers, equity analysts, the press and other stakeholders are invited to participate in the presentation, where CEO Per Nilsson and acting CFO Ebba Pilo Karth will comment on the results for January-March 2024. Following the presentation, it will be possible to ask questions. The presentation will be given in Swedish and can be followed live

ABGSC to publish Q1 2024 Interim Report on 18 April

ABG Sundal Collier (“ABGSC”) will publish its Q1 2024 figures on 18 April 2024 at 08:00 CEST. The report will be available on our corporate website www.abgsc.com. Webcast presentation CEO Jonas Ström will present the Q1 results through a webcast at 09:00 CEST, followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information: Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts: Anna Tropp, Head of Communications, +46 722 30 94 17

There are no items matching the current filter
There are no more items matching the current filter
Back to top